aDepartment of Ophthalmology, University Medical Center Utrecht, University Utrecht, the Netherlands bDepartment of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, ...

OXFORD, UK I April 9, 2025 I Infinitopes Ltd today announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial ...

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the ...

Beyond its role in the initiation of digestion, the oral microbiome appears to be key to maintaining both oral and systemic ...

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

Mapping an antibody’s epitope, where it binds a target, can now be done in three dimensions, which optimizes the selection of application-specific antibodies.

Explore how machine learning is transforming immunology—from epitope prediction to smarter vaccine design—plus key challenges and future directions.